Key terms

About BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BAX news

Yesterday 6:02am ET Exact Sciences names Aaron Bloomer as CFO, effective May 15 Apr 11 8:35am ET Baxter announces continued expansion of its pharmaceuticals portfolio Apr 03 5:51am ET Baxter price target raised to $44 from $41 at Citi Apr 02 5:27am ET Baxter’s Novum IQ Launch: A Hold Rating Amid Competitive Challenges and Market Opportunities Apr 02 3:50am ET Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA) Apr 01 7:27am ET FDA clears Baxter’s Novum IQ LVP and dose IQ safety software Mar 05 7:54am ET Baxter price target raised to $45 from $42 at BofA Mar 05 7:51am ET Baxter discloses recent talks with PE investors on potential sale of Kidney Care Mar 05 5:03am ET Baxter International Hold Rating: Assessing Kidney Care Asset Sale Versus Spin-Off Feb 29 11:05am ET Baxter call volume above normal and directionally bullish Feb 29 6:31am ET Barclays Sticks to Its Buy Rating for Baxter International (BAX) Feb 12 5:45am ET Baxter price target raised to $54 from $52 at Barclays Feb 11 8:20pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Baxter International (BAX) and Waters (WAT) Feb 10 1:01am ET New Share Price & Shareholder Rights Risk for Baxter International Inc – What’s the Latest? Feb 09 9:18am ET Baxter price target raised to $42 from $35 at Deutsche Bank Feb 09 8:28am ET Baxter International (BAX) Gets a Buy from Stifel Nicolaus Feb 08 4:36pm ET Baxter International: A Strong Buy on Robust Financial Performance and Growth Prospects Feb 08 7:26am ET Baxter sees FY24 adjusted EPS $2.85-$2,95, consensus $2.93 Feb 08 7:25am ET Baxter sees Q1 adjusted EPS 59c-62c, consensus 62c Feb 08 7:23am ET Baxter reports Q4 adjusted EPS 88c, consensus 86c Feb 07 8:25pm ET Notable companies reporting before tomorrow’s open Feb 07 1:21pm ET Notable companies reporting before tomorrow’s open Feb 05 8:15am ET Stifel Nicolaus Reaffirms Their Buy Rating on Baxter International (BAX)

No recent press releases are available for BAX

BAX Financials

1-year income & revenue

Key terms

BAX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BAX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms